Albumin in Cardiac Surgery (ALBICS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02560519|
Recruitment Status : Recruiting
First Posted : September 25, 2015
Last Update Posted : May 10, 2019
Colloid solutions are widely used for volume replacement therapy because of their high oncotic pressure, which could reduce interstitial fluid shifting. Human albumin is the only colloid solution of biologic origin with a molecular weight of 60 kDa. As the most abundant plasma protein, it has physiological importance in the well-being of the endothelial glycocalyx. Older studies in septic patients, however, did not show any benefit of albumin over saline solution. Crystalloid solutions, such as Ringer's acetate, do not impair neither renal function nor coagulation, but their volume expanding effect is questionable.
For several reasons (use of heart-lung machine, systemic inflammation, coagulation disturbances), patients undergoing cardiac surgery need especially large amounts of fluids. However, there are no large trials comparing albumin solutions to crystalloid solutions cardiac surgery.
This double-blinded trial will randomize according to a power analysis 1250 cardiac surgery patients (=625+625) at Meilahti hospital to use either 4% Albumin or Ringer's acetate solutions for both priming of the heart-lung machine and perioperative volume replacement therapy. The primary efficacy and safety endpoint of this study is the incidence of major adverse events (MAE), defined as a composite endpoint of all-cause mortality, acute myocardial infarction, acute heart failure or low output syndrome, resternotomy, stroke, certain arrhythmias, major bleeding, infections compromising post-procedural rehabilitation, acute kidney injury within 90 days postoperatively. The secondary outcomes are total number of MAEs, major adverse cardiac events (MACE), perioperative fluid balance, blood product transfusions, blood loss, acute kidney injury, days alive without mechanical ventilation/outside ICU/at home in 90 days as well as 90-day mortality. Blood samples for biochemical analyses will be collected at four perioperative time points.
This trial will provide data about efficacy and safety of 4% albumin in cardiac surgery patients. The biochemical mechanisms of albumin will be assessed.
|Condition or disease||Intervention/treatment||Phase|
|C.Surgical Procedure; Cardiac||Drug: Albumin solution Drug: Ringers acetate solution||Phase 4|
The use of cardiopulmonary bypass (CPB) between two study solutions: albumin solution with the final concentration of 4% and Ringer's acetate solution. The trial consists of two phases as follows. For each patient, one and the same study solution will used in both phases of the trial according to randomization.
In the first phase of the trial, the study solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of the study solution. See the Blinding section below for more details.
- Albumin group (trial group): A mixture of 20% (200 mg/mL) albumin solution (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution (see below) in the final albumin concentration of 4%.
- Ringer group (conventional group): Ringer's acetate solution (Ringer-acetate®, Baxter; pH 6.0, contents Na+ 131 mmol/L, Cl- 112 mmol/L, acetate 30 mmol/L) alone.
In the second phase of the trial, during surgery and the first 24 hours of ICU treatment, study solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not protocolled but will be based on the clinical decision.
Albumin group (trial group):4% (40 mg/mL) albumin(Albuman®, Sanquin, the Netherlands)
•Ringer group (conventional group): Ringer's acetate solution (Ringer-acetate®, Baxter; pH 6.0, contents Na+ 131 mmol/L, Cl- 112 mmol/L, acetate 30 mmol/L) The trial will end after the first 24 hours of ICU treatment or when the patient leaves the ICU if the latter occurs within the first postoperative 24 hours. After the study period, fluids are administered according to the local clinical practice.
The use of blood products, excluding albumin, is not protocolled, but will be based on the clinical decision.
For physiological basic need of fluid, Ringer's acetate solution will be given throughout the study period, i.e. during surgery and postoperatively, as a background infusion of 0.5 ml/kg/h, rounded to the nearest multible of 10 ml.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1250 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Albumin vs Ringer Solution for Cardiac Surgery|
|Actual Study Start Date :||March 21, 2017|
|Estimated Primary Completion Date :||February 2020|
|Estimated Study Completion Date :||March 2020|
Active Comparator: Ringers acetate solution
Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
Drug: Ringers acetate solution
The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.
During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision.
Experimental: Albumin solution
Albuman® 200g/L (Sanquin, the Netherlands) is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.The solution contains 100 mmol/l of sodium (2.3 g/L). Pharmacodynamic properties: Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Pharmacokinetic properties. Under normal conditions, the average half-life of albumin is about 19 days. Albuman® 40g/L is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin. The solution contains 140 mmol/l of sodium (3.2 g/L).
Drug: Albumin solution
Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.
During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision.
Other Name: Albumin
- Major adverse events [ Time Frame: 90 days ]The number of patients with at least one major adverse event during 90 days postoperatively:all-cause death;acute myocardial injury (increase in CK-MB at least 10 times as high as the upper normal limit);new onset of acute heart failure/low output syndrome requiring intravenous inotropic agents,intra-aortic balloon pump support and/or ECMO,resternotomy/subxiphoidal pericardial drainage;stroke;major arrhythmia (ventricular fibrillation off-CPB,ventricular tachycardia off-CPB,new onset atrial fibrillation of permanent nature requiring anticoagulation, permanent pacing dependency of new onset);major bleeding (chest tube blood loss at 18 hours over 20 mL/kg) or requiring 5 or more units of red blood cell transfusion or an equivalent volume of washed red blood cells within intervention time;infection compromising post-procedural rehabilitation;acute kidney injury(postoperative increase of creatinine at least 2 times compared to the preoperative level),renal replacement therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02560519
|Contact: Eero Pesonen, MD;PhDemail@example.com|
|Contact: Maxim Mazanikov, MD;PhDfirstname.lastname@example.org|
|Helsinki University Central Hospital, Meilahti Hospital||Recruiting|
|Helsinki, Uusimaa, Finland, 00029|
|Contact: Eero Pesonen, MD.,PhD email@example.com|
|Study Chair:||Eero Pesonen, MD.,PhD||Helsinki University Central Hospital|
|Principal Investigator:||Hanna Vlasov, MD||Helsinki University Central Hospital|